Varenicline for tobacco dependence: panacea or plight?

Bibliography

• Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006;166:1553-9
   PubMed Web of Science ®Google Scholar
• Coe JW, Brooks PR, Vetelino MG, Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7
   PubMed Web of Science ®Google Scholar
• Kuehn BM. FDA speeds smoking cessation drug review. JAMA 2006;295:614
   PubMedGoogle Scholar
• Fontanarosa PB, DeAngelis CD. Update on JAMA-EXPRESS Rapid Review and Publication. JAMA 2008;300:2920-1
   PubMedGoogle Scholar
• Gonzales D, Rennard SI, Nides M, Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. A randomized controlled trial. JAMA 2006;296:47-55
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, Efficacy of varenicline, an alpha4beta2nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. A randomized controlled trial. JAMA 2006;296:56-63
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tonnesen P, Hajek P, Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71
   PubMed Web of Science ®Google Scholar
• Obach RS, Reed-Hagen AE, Krueger SS, Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2006;34:121-30
   PubMed Web of Science ®Google Scholar
• Eisenberg MJ, Filion KB, Yavin D, Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008;179:135-44
   PubMed Web of Science ®Google Scholar
• Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006;6:300
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011;16
   Google Scholar
• Ravva P, Gastonguay MR, French JL, Quantitative assessment of exposure response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin Pharmacol Ther 2010;87:336-44
   PubMedGoogle Scholar
• Hughes JR, Keely JP, Niaura RS, Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res 2003;5:13-25
   PubMed Web of Science ®Google Scholar
• Dervaux A, Kanit M, Laqueille X. Efficacy of varenicline for smoking cessation. JAMA 2006;296:2555; author reply 2555-6
   PubMedGoogle Scholar
• Lasser KE, Boyd JW. Varenicline and smokers with mental illnesses. Lancet 2008;372:1218-19
   PubMedGoogle Scholar
• Lasser K, Boyd JW, Woolhandler S, Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-10
   PubMed Web of Science ®Google Scholar
• Hagman BT, Delnevo CD, Hrywna M, Williams JM. Tobacco use among those with serious psychological distress: findings from the National Survey of Drug Use and Health, 2002. Addict Behav 2008;33:582-92
   PubMed Web of Science ®Google Scholar
• Han ES, Foulds J, Steinberg MB, Characteristics and smoking cessation outcomes of patients returning for repeat tobacco dependence treatment. Int J Clin Pract 2006;60:1068-74
   PubMed Web of Science ®Google Scholar
• Piper ME, Smith SS, Schlam TR, Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. J Consult Clin Psychol 2010;78:13-23
   PubMed Web of Science ®Google Scholar
• McClure JB, Swan GE, Catz SL, Smoking outcome by psychiatric history after behavioral and varenicline treatment. J Subst Abuse Treat 2010;38:394-402
   PubMed Web of Science ®Google Scholar
• Clarke DE, Eaton WW, Petronis KR, Increased risk of suicidal ideation in smokers and former smokers compared to never smokers: evidence from the baltimore ECA follow-up study. Suicide Life Threat Behav 2010;40:307-18
   PubMed Web of Science ®Google Scholar
• Breslau N, Schultz LR, Johnson EO, Smoking and the risk of suicidal behavior: a prospective study of a community sample. Arch Gen Psychiatry 2005;62:328-34
   PubMed Web of Science ®Google Scholar
• Ostacher MJ, Nierenberg AA, Perlis RH, The relationship between smoking and suicidal behavior, comorbidity, and course of illness in bipolar disorder. J Clin Psychiatry 2006;67:1907-11
   PubMed Web of Science ®Google Scholar
• Oquendo MA, Bongiovi-Garcia ME, Galfalvy H, Sex differences in clinical predictors of suicidal acts after major depression: a prospective study. Am J Psychiatry 2007;164:134-41
   PubMed Web of Science ®Google Scholar
• Moriya F, Hashimoto Y, Furumiya J. Nicotine and cotinine levels in body fluids of smokers who committed suicide. Forensic Sci Int 2007;168(2–3):102-5
   Google Scholar
• Berlin I, Henian C, Covey LS. Depressive mood, suicide ideation and anxiety in smokers who do and smokers who do not manage to stop smoking after a target quit day. Addiction 2010;105:2209-16
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Studies linking smoking-cessation drug with suicide risk spark concerns. JAMA 2009;301:1007-8
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug Safety and Availability; 2010. Available from: www.fda.gov/Drugs/Drugsafety [Last accessed 1 March 2011]
   Google Scholar
• Moore TJ, Glenmullen J, Furberg CD. Thoughts and acts of aggression/violence toward others reported in association with varenicline. Ann Pharmacother 2010;44:1389-94
   PubMed Web of Science ®Google Scholar
• Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry 2008;165:774
   PubMed Web of Science ®Google Scholar
• Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007;164:1269
   PubMed Web of Science ®Google Scholar
• Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007;164:1269-70
   PubMed Web of Science ®Google Scholar
• Kutscher EC, Stanley M, Oehlke K. Chantix-induced mental status changes in a young healthy female. S D Med 2009;62:193-195
   PubMedGoogle Scholar
• DiPaula BA, Thomas MD. Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy 2009;29:852-7
   PubMed Web of Science ®Google Scholar
• Lyon GJ. Possible varenicline-induced paranoia and irritability in a patient with major depressive disorder, borderline personality disorder, and methamphetamine abuse in remission. J Clin Psychopharmacol 2008;28:720-1
   PubMed Web of Science ®Google Scholar
• Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008;13:511-14
   PubMed Web of Science ®Google Scholar
• Raidoo BM, Kutscher EC. Visual hallucinations associated with varenicline: a case report. J Med Case Reports 2009;3:7560
   PubMedGoogle Scholar
• Ismail Z, Syms J, Blumberger D, George TP. Varenicline induced polydipsia and hyponatremia in a patient with schizophrenia. Schizophr Res 2010;119:268
   PubMedGoogle Scholar
• Morstad AE, Kutscher EC, Kennedy WK, Carnahan RM. Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother 2008;42:288-9
   PubMed Web of Science ®Google Scholar
• Pirmoradi P, Roshan S, Nadeem SS. Neuropsychiatric disturbance after initiation of varenicline in a patient with a history of alcohol abuse and major depression. Am J Health Syst Pharm 2008;65:1624-6
   PubMed Web of Science ®Google Scholar
• Bird ML, Vesta KS. Varenicline-associated acute renal failure. Ann Pharmacother 2008;42:1908-11
   PubMedGoogle Scholar
• Duparc A, Gosset P, Caron J, Acute generalized exanthematous pustulosis caused by varenicline. J Eur Acad Dermatol Venereol 2009;23:1111-12
   PubMedGoogle Scholar
• Kristensen PL, Pedersen-Bjergaard U, Thorsteinsson B. Varenicline may trigger severe hypoglycaemia in type 1 diabetes. Diabet Med 2008;25:625-6
   PubMedGoogle Scholar
• Smith RC, Lindenmayer JP, Davis JM, Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009;110:149-55
   PubMed Web of Science ®Google Scholar
• Fatemi SH. Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res 2008;103:328-9
   PubMed Web of Science ®Google Scholar
• Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry 2008;69:1016
   PubMed Web of Science ®Google Scholar
• Anghelescu I. Successful smoking cessation and improvement of negative symptoms with varenicline in a stable schizophrenia patient. J Neuropsychiatry Clin Neurosci 2009;21:102-3
   PubMed Web of Science ®Google Scholar
• Weiner E, Buchholz A, Coffay A, Varenicline for smoking cessation in people with schizophrenia: a double blind randomized pilot study. Schizophr Res 2011;129(1):94-5
   Google Scholar
• McClure JB, Swan GE, Jack L, Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 2009;24:563-9
   PubMed Web of Science ®Google Scholar
• Philip NS, Carpenter LL, Tyrka AR, Varenicline augmentation in depresses smokers: an 8-week, open-label study. J Clin Psychiatry 2009;70:1026-31
   PubMed Web of Science ®Google Scholar
• Stapleton JA, Watson L, Spirling LI, Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103:146-54
   PubMed Web of Science ®Google Scholar
• Purvis TL, Mambourg SE, Balvanz TM, Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother 2009;43:862-7
   PubMed Web of Science ®Google Scholar
• Poling J, Rounsaville B, Gonsai K, The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict 2010;19:401-8
   PubMed Web of Science ®Google Scholar
• Steinberg MB, Bover MT, Richardson DL, Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. Drug Alcohol Depend 2011;114:77-81
   PubMedGoogle Scholar
• Gunnell D, Irvine D, Wise L, Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805
   PubMed Web of Science ®Google Scholar
• Tonstad S, Davies S, Flammer M, Psychiatric adverse events in randomized double-blind, placebo-controleld clinical trials of varenicline. A pooled analysis. Drug Saf 2010;33:289-301
   PubMed Web of Science ®Google Scholar
• Garza D, Murphy M, Tseng LJ, A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo. Biol Psychiatry 2011;69(11):1075-82
   Google Scholar
• Stapleton J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? Addiction 2009;104:864-5
   PubMed Web of Science ®Google Scholar
• Henningfield JE, Shiffman S, Ferguson SG, Gritz ER. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 2009;123:1-16
   PubMedGoogle Scholar
• Spiller K, Xi Z-X, Li X, Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of a4b2 nicotinic receptors in rats. Neuropharmacology 2009;57:60-6
   PubMed Web of Science ®Google Scholar
• Rollema H, Chambers LK, Coe JW, Pharmacological profile of the a4b2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007;52:985-94
   PubMed Web of Science ®Google Scholar
• McColl SL, Burstein AH, Reeves KR, Human abuse liability of the smoking cessation drug varenicline in smokers and nonsmokers. Clin Pharmacol Ther 2008;83:607-14
   PubMed Web of Science ®Google Scholar
• Perkins KA, Mercincavage M, Fonte CA, Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology 2010;210:45-51
   PubMedGoogle Scholar
• McKee SA, Harrison ELR, O'Malley SS, Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 2009;66:185-90
   PubMed Web of Science ®Google Scholar
• Patterson F, Jepson C, Strasser AA, Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry 2009;65:144-49
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Herman AI, Mooney M, Waters AJ. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology 2009;207:153-62
   PubMedGoogle Scholar
• Ebbert JO, Croghan IT, North F, Schroeder DR. A pilot study to assess smokeless tobacco use reduction with varenicline. Nicotine Tob Res 2010;12:1037-40
   PubMedGoogle Scholar
• West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology 2008;197:371-7
   PubMed Web of Science ®Google Scholar
• Williams KE, Reeves KR, Billing CB Jr, A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793-801
   PubMed Web of Science ®Google Scholar
• Russ C, Rennard S, Arteaga C, Hughes J. Is setting a quit date a priori essential? A comparison of studies of varenicline using flexible vs. a priori quit date protocols. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) 17th Annual Meeting, 16 – 19 February 2011, Westin Harbour Castle, Toronto, Canada
   Google Scholar
• Niaura R, Hays JT, Jorenby DE, The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin 2008;24:1931-41
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Bobak A, Britton JR, Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63:717-24
   PubMed Web of Science ®Google Scholar
• Fiore MC, Jaen CR, Baker TB, Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service, 2008
   Google Scholar
• Issa JS, Ogawa TM, Soares de Moura AS, Pereira AC. Effectiveness of varenicline combination therapy in real life setting: PAF database study. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) 17th Annual Meeting, 16 – 19 February 2011, Westin Harbour Castle, Toronto, Canada
   Google Scholar
• Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009;11:572-6
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Pipe AL, Benowitz NL, Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221-9
   PubMed Web of Science ®Google Scholar
• Willers S. Smoking cessation treatment using varenicline in a patient population with mostly heart and lung diseases. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, 16 – 19 February 2011, Westin Harbour Castle, Toronto, Canada
   Google Scholar
• Tashkin DP, Rennard S, Hays JT, Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized controlled trial. Chest 2011;139(3):591-9
   Google Scholar
• Steinberg MB, Randall J, Greenhaus S, Tobacco dependence treatment intervention for hospitalized smokers: a pilot randomized, controlled trial. Poster presented at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting, 16 – 19 February 2011, Westin Harbour Castle, Toronto, Canada
   Google Scholar
• Xiao Y, Lv Y, Zhang X, The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. Int J Clin Pharmacol Ther 2009;47:246-54
   PubMedGoogle Scholar
• Baha MY, Le Faou AL. Smoking cessation interventions offered to French adult light smokers: a heterogeneous population with specific needs. Eur Addict Res 2010;16:162-9
   PubMedGoogle Scholar
• Fagerstrom K, Gilljam H, Metcalfe M, Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. BMJ 2010;341:c6549
   PubMedGoogle Scholar